Shilpa Medicare announces positive Phase 3 results for Oeris
OERIS offers extended antiemetic coverage through a single injection that effectively prevents both acute and delayed CINV for up to five days
OERIS offers extended antiemetic coverage through a single injection that effectively prevents both acute and delayed CINV for up to five days
New funding to advance non-surgical brain interface technology and expand clinical and engineering capabilities globally
Dragon Copilot integrates generative AI, ambient listening, and natural language processing (NLP) to capture and document care directly
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
Enabling a new era in minimally invasive obesity treatment across Europe
While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage
The upcoming facility marks a strategic milestone in SOUKYA’s mission to make evidence-based holistic healthcare
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
The offering is expected to close on November 10, 2025, subject to customary closing conditions
Subscribe To Our Newsletter & Stay Updated